[68Ga]Ga-PSMA-11

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

10 competitors in Metastatic Neuroendocrine Prostate Cancer

#DrugCompanyPhaseTrials

1

Reglan

IIstituto Clinico Humanitas

Phase 1

12

[68ga]ga-DOTA-TATE

Novartis

Phase 1

13

[68ga]ga-Neob

Novartis

Phase 1

14

[177lu]lu-DOTA-TATE

Novartis

Phase 1

15

[177lu]lu-Neob

Novartis

Phase 1

16

Gonadotropin-Releasing Hormone (gnrh) Analogues

Novartis

Phase 1

17

Gnrh Antagonists

Novartis

Phase 1

18

[68Ga]Ga-PSMA-11

Novartis

Phase 1

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting·Novartis·Phase 1·NCT06379217·31 enrolled

Details

Drug Info

Related News